Global vs. Focal Neuroimaging Markers of Dementia Risk

痴呆风险的整体与局灶神经影像标记

• 批准号: 7102254
• 负责人: Caterina Rosano
• 金额: $ 6.53万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-15 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7102254
• 关键词: Alzheimer' s disease; bioimaging /biomedical imaging; biomarker; brain imaging /visualization /scanning; brain mapping; brain morphology; clinical research; cognition; cognition disorders; computer assisted diagnosis; dementia; diagnosis design /evaluation; disease /disorder proneness /risk; hippocampus; human data; magnetic resonance imaging; meta analysis; neural degeneration; pathologic process; technology /technique development; temporal lobe /cortex

DESCRIPTION (provided by applicant): Our goal is to identify and quantify specific neuroimaging markers of Alzheimer Disease (AD) using an automated brain MRI reading technique, the automated labeling pathway (ALP). ALP is a reliable, easy to operate, fully automated technique that generates regional and global volumetric measures of the brain. This self-contained project proposes secondary analysis of 532 brain MRIs acquired in Pittsburgh in 1997-99 as part of the Cardiovascular Health Study (CHS; N01HC85082), a multisite observational study to investigate cardiovascular risk factors in the elderly. CHS participants received a detailed dementia evaluation as part of the Cognition Study of the CHS (CHS-CS; R01AGO15928). Our project will take advantage of the wealth of epidemiologic data collected from 1989 to date, including the follow-up dementia evaluation conducted in Pittsburgh by Dr. Lopez (R01AG020098). ALP volumetric measures of the brain will enrich the CHS-CS dataset and will be available to other CHS investigators. We propose that ALP- measures of global and focal atrophy (hippocampal and medial temporal lobe): 1) differentiate older individuals who are cognitively normal, vs. those who are affected by AD or Mild Cognitive Impairment; 2) discriminate cases of dementia better than conventional CHS-CS brain MRI measures (ventricular and white matter grade); 3) discriminate those cognitively normal adults who convert to dementia over the following 5 years vs. those who convert to MCI or remain cognitively normal. The strengths of this application include: immediate availability of 532 brain MRIs in Pittsburgh, well documented cases of dementia from 1989 to- date, local support for the use of ALP, extensive demographic, genetic and clinical data. In accordance to the Final Consensus of the NIA Alzheimer's initiative, we will evaluate the convergent validity of measures from novel and conventional brain MRI reading methods, and will test if diagnosis of dementia can improve when specific neuroimaging biomarkers are included in the diagnostic criteria. We also plan to optimize and support the use of the ALP method by other investigators. The results of this proposal will lay a foundation for a future RO1 application to assess neuroimaging markers of dementia risk in a sample of over 3,000 CHS participants, for whom repeated MRIs and over 15 years follow up data on dementia are available.

描述（由申请人提供）：我们的目标是使用自动化标签途径（ALP）识别和量化阿尔茨海默氏病（AD）的特定神经成像标记。 ALP是一种可靠，易于操作，完全自动化的技术，可生成大脑的区域和全球体积测量。这个独立的项目提出了对1997 - 99年在匹兹堡获得的532个大脑MRIS的二级分析，作为心血管健康研究（CHS; N01HC85082）的一部分，这是一项多站点观察性研究，以研究老年人的心血管危险因素。 CHS参与者接受了详细的痴呆评估，作为CHS认知研究（CHS-CS; R01AGO15928）的一部分。我们的项目将利用从1989年到目前为止收集的大量流行病学数据，包括洛佩兹博士在匹兹堡进行的后续痴呆评估（R01AG020098）。大脑的ALP体积测量方法将丰富CHS-CS数据集，并将提供其他CHS研究人员。我们提出，全球和局灶性萎缩（海马和内侧颞叶）的ALP测量：1）区分认知正常的老年人，与受AD或轻度认知障碍影响的年龄段； 2）比常规的CHS-CS脑MRI测量（心室和白质等级）更好地区分痴呆病例； 3）歧视那些在接下来的5年中转化为痴呆症的认知正常成年人，而转换为MCI或保持正常状态的成年人。该应用程序的优势包括：匹兹堡的532脑MRI，从1989年到日期的痴呆症病例，局部支持ALP，广泛的人口统计学，遗传和临床数据。根据NIA阿尔茨海默氏症计划的最终共识，我们将评估新颖和常规的大脑MRI阅读方法的措施的收敛有效性，并将测试当诊断标准中包括特定的神经影像生物标志物时，痴呆症的诊断是否可以改善。我们还计划优化和支持其他研究人员对ALP方法的使用。该提案的结果将为未来的RO1应用奠定基础，以评估3,000多名CHS参与者的样本中的痴呆风险标记，为此，他们重复进行了MRI和15年以上的跟进痴呆症数据。